Tandem Diabetes Care INC

Tandem Diabetes Care's stockholders approved key amendments to its charter and its long-term incentive plan at the 2026 Annual Meeting.

Tandem Diabetes Care announced the termination of its Chief Commercial Officer, Mark Novara, effective May 18, 2026, stating the company's strategy remains unchanged.

Tandem Diabetes Care reported record first quarter pump shipments and sales, with revenue reaching $247.2 million and gross margin improving to 55%.

Tandem Diabetes Care, Inc. completed a private offering of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, including the full exercise of the initial purchasers' option.

Tandem Diabetes Care reported record Q4 2025 sales and surpassed $1 billion in full-year worldwide sales, while providing 2026 financial guidance.

Tandem Diabetes Care, Inc. adopted amended and restated bylaws, updating corporate governance provisions related to shareholder nominations, meeting procedures, and indemnification.

Tandem Diabetes Care announced its first quarter 2026 financial results, showing increased sales and improved gross margin, but a net loss.

Tandem Diabetes Care reports increased sales and improved gross margins for Q3 and YTD 2025, but a significant rise in year-to-date net loss driven by one-time expenses.

Tandem Diabetes Care reported a wider net loss in the second quarter of 2025, driven by significant litigation settlement expenses and increased R&D investments, despite an increase in sales.

Tandem Diabetes Care's Q1 2025 revenue increased year-over-year, but a significant charge related to the AMF Medical acquisition contributed to a larger net loss.

Tandem Diabetes Care's Q3 2024 results show a significant increase in revenue and pump shipments compared to the same period last year, despite ongoing operating losses.

Tandem Diabetes Care's second quarter 2024 results show increased sales but a net loss, reflecting ongoing investments and market shifts.

Tandem Diabetes Care reported increased worldwide sales to over $1 billion in 2025, driven by higher pump shipments and international expansion, despite incurring significant net operating losses.

Tandem Diabetes Care's 2024 10-K filing reveals a year of strategic transitions, including portfolio expansion and international growth, alongside ongoing financial challenges and evolving market dynamics.

Tandem Diabetes Care's 10-K filing details its capital stock, potential risks, and strategic direction in the competitive diabetes technology market.

Leigh Vosseller, EVP & CHIEF FINANCIAL OFFICER of Tandem Diabetes Care Inc, reported multiple transactions in common stock on August 15, 2026.

Jean-Claude Kyrillos, EVP & Chief Operating Officer of Tandem Diabetes Care Inc, reported multiple transactions in common stock on July 15, 2026.

Elizabeth Anne Gasser, EVP, Chief Strategy Officer at Tandem Diabetes Care Inc., transferred 7,160 shares of common stock to a family trust on June 2, 2026.

Tandem Diabetes Care Inc. reports that President & CEO John F. Sheridan was granted 191,103 restricted stock units under the company's 2023 Long-Term Incentive Plan.

Elizabeth Gasser, EVP, Chief Strategy Officer at Tandem Diabetes Care, was granted 29,136 Restricted Stock Units on May 29, 2026.

Leigh Vosseller, EVP & CFO of Tandem Diabetes Care, received a grant of 62,657 Restricted Stock Units (RSUs) on May 29, 2026.

Tandem Diabetes Care, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026, detailing proposals for director elections, executive compensation, and plan amendments.

Tandem Diabetes Care is asking shareholders to vote on key proposals, including declassifying the board structure and ratifying Ernst & Young as the independent auditor.

Tandem Diabetes Care will hold its 2025 Annual Meeting of Stockholders virtually on May 21, 2025, to vote on the election of directors, executive compensation, the frequency of say-on-pay votes, and the ratification of the company's independent auditor.

Tandem Diabetes Care is asking shareholders to vote on key proposals including declassifying the board structure, increasing shares under employee stock purchase and long-term incentive plans, executive compensation, and ratifying the appointment of Ernst & Young LLP as the independent auditor.

Tandem Diabetes Care is asking stockholders to approve amendments to its 2013 Employee Stock Purchase Plan and 2023 Long-Term Incentive Plan to increase the number of shares available for issuance.

Voya Financial, Inc. has filed a Schedule 13G, disclosing a passive ownership of 0.2% in Tandem Diabetes Care Inc. common stock.

Voya Financial, Inc. has reported beneficial ownership of 4,343,683 shares, representing 6.3% of Tandem Diabetes Care Inc.'s common stock, as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.18% of Tandem Diabetes Care Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.91% in Tandem Diabetes Care Inc., holding over 4 million shares.

The Vanguard Group reports 0% beneficial ownership in Tandem Diabetes Care Inc. following an internal realignment.

ArrowMark Colorado Holdings, LLC has reported a 5.46% beneficial ownership stake in Tandem Diabetes Care Inc. common stock.